Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron Pharmaceuticals serves the healthcare sector in the United States.
Website: regeneron.com



Growth: Pretty weak revenue growth rate 9.0%, there is slowdown compared to average historical growth rates 13.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +26.7%

Profitability: LTM EBITDA margin is positive, +62.6%. On average the margin is decreasing unsteadily. Gross margin is high, +85.0%. In the last quarter the company beat the estimated EPS, +5.5%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$1.48 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 2.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 85.1% higher than minimum and 10.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.2x by EV / Sales multiple , the company can be 55.4% overvalued

Insiders: For the last 3 months insiders sold company shares on $39.6 mln (-0.039% of cap.)

Key Financials (Download financials)

Ticker: REGN
Share price, USD:  (-1.7%)890.68
year average price 839.79  


year start price 801.79 2023-04-28

min close price 692.45 2023-07-07

max close price 993.35 2024-02-27

current price 890.68 2024-04-26
Common stocks: 107 100 000

Dividend Yield:  0.0%
FCF Yield LTM: 2.0%
EV / LTM EBITDA: 18.5x
EV / EBITDA annualized: 19.5x
Last revenue growth (y/y):  9.0%
Last growth of EBITDA (y/y):  -14.3%
Historical revenue growth:  13.3%
Historical growth of EBITDA:  21.9%
EV / Sales: 11.6x
Margin (EBITDA LTM / Revenue): 62.6%
Fundamental value created in LTM:
Market Cap ($m): 95 392
Net Debt ($m): -13 538
EV (Enterprise Value): 81 854
Price to Book: 3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25Reuters

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

2024-04-16Zacks Investment Research

Why Regeneron (REGN) Could Beat Earnings Estimates Again

2024-04-15Reuters

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

2024-04-12Zacks Investment Research

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

2024-04-11Investopedia

Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch

2024-04-11Proactive Investors

Regeneron Pharma falls after US government alleges fraud

2024-03-26Seeking Alpha

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

2024-03-26Zacks Investment Research

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

2024-03-25Reuters

US FDA declines to approve Regeneron's blood cancer therapy

2024-03-12Zacks Investment Research

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589
fillingDate 2024-02-05 2023-11-02 2023-08-03 2023-05-04 2023-02-06 2022-11-03
acceptedDate 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 3 434M 3 363M 3 158M 3 162M 3 414M 2 936M
costOfRevenue 517M 212M 405M 458M 541M 318M
grossProfit 2 917M 3 151M 2 753M 2 705M 2 874M 2 618M
grossProfitRatio 0.849 0.937 0.872 0.855 0.842 0.892
researchAndDevelopmentExpenses 1 177M 1 075M 1 085M 1 101M 1 043M 911M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 738M 641M 652M 601M 661M 529M
otherExpenses -900 000 -16M 85M -500 000 -7M -46M
operatingExpenses 1 914M 1 716M 1 737M 1 702M 1 697M 1 395M
costAndExpenses 2 431M 1 928M 2 142M 2 159M 2 238M 1 713M
interestIncome 149M 134M 0 0 0 0
interestExpense 18M -18M 19M 18M 17M 15M
depreciationAndAmortization 113M 105M 103M 85M 225M 394M
ebitda 1 264M 1 111M 1 205M 1 032M 1 372M 1 618M
ebitdaratio 0.368 0.330 0.382 0.326 0.402 0.551
operatingIncome 973M 1 111M 1 017M 947M 1 147M 1 224M
operatingIncomeRatio 0.283 0.330 0.322 0.299 0.336 0.417
totalOtherIncomeExpensesNet 14M -200 000 85M -89M 178M 286M
incomeBeforeTax 1 148M 1 111M 1 083M 858M 1 325M 1 510M
incomeBeforeTaxRatio 0.334 0.330 0.343 0.271 0.388 0.514
incomeTaxExpense -12M 103M 115M 40M 128M 194M
netIncome 1 160M 1 008M 968M 818M 1 197M 1 316M
netIncomeRatio 0.338 0.300 0.307 0.259 0.351 0.448
eps 10.880 9.480 9.050 7.640 11.190 12.310
epsdiluted 10.190 8.890 8.500 7.170 10.500 11.660
weightedAverageShsOut 107M 106M 114M 107M 107M 107M
weightedAverageShsOutDil 114M 113M 114M 114M 114M 113M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589
fillingDate 2024-02-05 2023-11-02 2023-08-03 2023-05-04 2023-02-06 2022-11-03
acceptedDate 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 2 730M 2 152M 1 937M 3 916M 3 106M 3 491M
shortTermInvestments 8 115M 7 761M 6 991M 5 043M 4 636M 3 530M
cashAndShortTermInvestments 10 845M 9 914M 8 928M 8 960M 14 334M 7 022M
netReceivables 5 667M 5 585M 5 121M 5 119M 5 329M 5 548M
inventory 2 581M 2 562M 2 008M 1 870M 2 402M 2 412M
otherCurrentAssets 387M 575M 361M 406M 933M 446M
totalCurrentAssets 19 479M 18 635M 16 923M 16 909M 22 065M 15 429M
propertyPlantEquipmentNet 4 146M 4 006M 3 923M 3 881M 3 763M 3 704M
goodwill 0 0 0 0 0 0
intangibleAssets 1 039M 1 017M 953M 929M 916M 804M
goodwillAndIntangibleAssets 1 039M 1 017M 953M 929M 916M 804M
longTermInvestments 5 397M 5 779M 6 327M 6 067M 5 406M 5 969M
taxAssets 2 575M 2 317M 2 139M 1 925M 1 724M 1 452M
otherNonCurrentAssets 444M 410M 393M 350M -4 659M 320M
totalNonCurrentAssets 13 601M 13 529M 13 735M 13 151M 7 150M 12 249M
otherAssets 0 0 0 0 0 0
totalAssets 33 080M 32 163M 30 658M 30 060M 29 215M 27 678M
accountPayables 607M 537M 547M 600M 589M 536M
shortTermDebt 0 0 0 0 720M 0
taxPayables 0 0 0 0 300 000 0
deferredRevenue 459M 417M 381M 426M 548M 547M
otherCurrentLiabilities 2 358M 2 645M 2 176M 2 074M 1 992M 1 796M
totalCurrentLiabilities 3 423M 3 599M 3 104M 3 100M 3 849M 2 879M
longTermDebt 2 703M 2 703M 2 702M 2 702M 2 701M 2 701M
deferredRevenueNonCurrent 127M 125M 116M 86M 70M 60M
deferredTaxLiabilitiesNonCurrent 50M 0 0 0 0 0
otherNonCurrentLiabilities 804M 832M 717M 677M -70M 2 277M
totalNonCurrentLiabilities 3 684M 3 660M 3 535M 3 465M 2 701M 3 360M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 720M 720M 720M 720M 720M 720M
totalLiabilities 7 107M 7 259M 6 640M 6 565M 6 551M 6 239M
preferredStock 0.000 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings 27 260M 26 101M 25 093M 24 125M 23 307M 22 110M
accumulatedOtherComprehensiveIncomeLoss -81M -177M -198M -182M -239M -275M
othertotalStockholdersEquity -1 206M -1 020M -877M -448M -404M -396M
totalStockholdersEquity 25 973M 24 904M 24 018M 23 495M 22 664M 21 439M
totalEquity 25 973M 24 904M 24 018M 23 495M 22 664M 21 439M
totalLiabilitiesAndStockholdersEquity 33 080M 32 163M 30 658M 30 060M 29 215M 27 678M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 33 080M 32 163M 30 658M 30 060M 29 215M 27 678M
totalInvestments 16 241M 7 761M 6 991M 5 043M 10 043M 9 499M
totalDebt 2 703M 2 703M 2 702M 2 702M 3 421M 2 701M
netDebt -27M 550M 765M -1 215M 316M -790M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REGN REGN REGN REGN REGN REGN
reportedCurrency USD USD USD USD USD USD
cik 872 589 872 589 872 589 872 589 872 589 872 589
fillingDate 2024-02-05 2023-11-02 2023-08-03 2023-05-04 2023-02-06 2022-11-03
acceptedDate 2024-02-05 09:16:15 2023-11-02 07:22:07 2023-08-03 06:56:05 2023-05-04 07:14:54 2023-02-06 09:23:24 2022-11-03 07:25:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 160M 1 008M 968M 818M 1 197M 1 316M
depreciationAndAmortization 113M 105M 103M 100M 100M 93M
deferredIncomeTax -286M -126M -209M -217M -280M -86M
stockBasedCompensation 240M 204M 202M 239M 232M 166M
changeInWorkingCapital -61M -192M -81M 241M 382M -667M
accountsReceivables -83M -464M -3M 210M 220M -387M
inventory -47M -77M -100M -47M -144M -224M
accountsPayables 26M 303M 40M 119M 348M -160M
otherWorkingCapital 43M 45M -18M -41M -41M 104M
otherNonCashItems -76M 115M 40M 187M 88M -193M
netCashProvidedByOperatingActivities 1 090M 1 114M 1 022M 1 368M 1 720M 629M
investmentsInPropertyPlantAndEquipment -314M -176M -113M -279M -252M -1 069M
acquisitionsNet -4M 200M 134M 101M 1 617M 0
purchasesOfInvestments -2 132M -3 243M -4 522M -1 749M -3 143M -570M
salesMaturitiesOfInvestments 2 383M 2 998M 2 269M 1 793M 1 537M 1 832M
otherInvestingActivites 189M -275M -155M -101M -1 617M 0
netCashUsedForInvestingActivites -66M -496M -2 387M -236M -1 858M 192M
debtRepayment 0 0 0 0 0 0
commonStockIssued 301M 269M 91M 485M 373M 319M
commonStockRepurchased -747M -676M -705M -808M -620M -1 044M
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -458M -129M 0 0 0 0
netCashUsedProvidedByFinancingActivities -446M -407M -614M -323M -248M -725M
effectOfForexChangesOnCash 200 000 -200 000 3 765M 0 0 0
netChangeInCash 578M 211M -1 979M 809M -385M 96M
cashAtEndOfPeriod 2 738M 2 160M 1 950M 3 929M 3 119M 3 505M
cashAtBeginningOfPeriod 2 160M 1 950M 3 929M 3 119M 3 505M 3 409M
operatingCashFlow 1 090M 1 114M 1 022M 1 368M 1 720M 629M
capitalExpenditure -314M -176M -113M -279M -252M -1 069M
freeCashFlow 776M 938M 909M 1 089M 1 468M -440M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-02 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-03 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-02 11:30 ET
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2024-02-02 11:00 ET
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
2024-01-30 12:00 ET
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
2024-01-25 19:29 ET
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
2024-01-24 17:05 ET
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
2024-01-24 17:00 ET
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
2024-01-16 12:00 ET
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
2024-01-08 12:30 ET
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
2024-01-05 21:05 ET
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
2023-12-18 21:05 ET
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 12:30 ET
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
2023-12-11 00:30 ET
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
2023-12-10 17:30 ET
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
2023-12-07 12:00 ET
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
2023-12-07 07:30 ET
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
2023-11-30 21:05 ET
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
2023-11-27 06:30 ET
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
2023-11-15 21:05 ET
Regeneron Announces Investor Conference Presentation
2023-11-13 14:00 ET
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
2023-11-03 11:00 ET
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
2023-11-02 10:30 ET
Regeneron Reports Third Quarter 2023 Financial and Operating Results
2023-11-01 20:00 ET
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
2023-10-26 20:00 ET
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
2023-10-25 20:05 ET
Regeneron Announces Investor Conference Presentations
2023-10-22 18:59 ET
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
2023-10-21 12:48 ET
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
2023-10-20 21:00 ET
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
2023-10-18 13:30 ET
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
2023-10-18 13:00 ET
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
2023-10-15 22:05 ET
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
2023-10-05 13:43 ET
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
2023-10-03 11:00 ET
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
2023-09-29 12:30 ET
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
2023-09-28 20:05 ET
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
2023-09-26 05:29 ET
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
2023-09-25 12:34 ET
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
2023-09-08 20:46 ET
Regeneron Provides Update on Planned Chief Financial Officer Transition
2023-09-08 20:45 ET
Regeneron Announces Updates to Board of Directors
2023-08-23 20:05 ET
Regeneron Announces Investor Conference Presentations
2023-08-22 18:15 ET
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
2023-08-18 22:35 ET
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
2023-08-18 17:43 ET
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
2023-08-17 12:30 ET
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
2023-08-10 11:00 ET
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
2023-08-03 10:30 ET
Regeneron Reports Second Quarter 2023 Financial and Operating Results
2023-08-01 11:00 ET
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
2023-07-29 18:25 ET
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
2023-06-29 20:01 ET
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
2023-06-27 18:46 ET
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
2023-06-27 18:45 ET
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
2023-05-25 21:05 ET
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
2023-05-25 21:00 ET
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
2023-05-21 18:18 ET
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
2023-05-19 19:32 ET
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
2023-05-19 16:54 ET
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
2023-05-18 20:01 ET
Regeneron Announces Investor Conference Presentations
2023-05-18 15:45 ET
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
2023-05-04 10:30 ET
Regeneron Reports First Quarter 2023 Financial and Operating Results
2023-05-02 11:00 ET
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
2023-04-17 11:30 ET
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
2023-04-17 11:00 ET
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
2023-04-11 20:00 ET
Regeneron Announces Investor Conference Presentations
2023-04-03 20:00 ET
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
2023-03-29 11:00 ET
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
2023-03-28 11:30 ET
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
2023-03-28 11:30 ET
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
2023-03-23 06:00 ET
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
2023-03-22 11:00 ET
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
2023-03-21 05:59 ET
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
2023-03-18 14:00 ET
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
2023-03-15 02:56 ET
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
2023-03-15 01:30 ET
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
2023-03-07 06:00 ET
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
2023-03-01 01:00 ET
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
2023-02-24 12:45 ET
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
2023-02-23 12:00 ET
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
2023-02-21 12:00 ET
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
2023-02-08 23:45 ET
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
2023-02-03 11:30 ET
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
2023-01-31 21:01 ET
Regeneron Announces Investor Conference Presentations
2023-01-30 06:00 ET
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
2023-01-27 05:59 ET
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
2023-01-24 17:02 ET
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition
2023-01-24 17:00 ET
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
2023-01-03 21:01 ET
Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
2022-12-23 13:30 ET
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
2022-12-21 22:29 ET
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
2022-12-19 21:01 ET
Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-16 12:29 ET
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
2022-12-15 05:59 ET
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
2022-12-12 22:30 ET
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
2022-12-12 15:00 ET
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
2022-12-12 12:30 ET
Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
2022-12-11 15:30 ET
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
2022-12-01 12:00 ET
Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

SEC forms

Show financial reports only

SEC form 10
2024-02-05 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
Regeneron Pharmaceuticals reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 07:22 ET
Regeneron Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-02 07:10 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-05 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 06:56 ET
Regeneron Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 06:48 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-14 16:07 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-10 07:01 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 8
2023-04-10 00:00 ET
Regeneron Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-29 16:01 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-06 09:23 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-06 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-03 07:06 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:49 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Regeneron Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-20 16:01 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 07:25 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 07:19 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-05 16:04 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 07:17 ET
Regeneron Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-03 07:21 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 07:08 ET
Regeneron Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-15 16:11 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-02 07:36 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 07:17 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 07:08 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Regeneron Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-21 16:09 ET
Regeneron Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-08 06:15 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-07 09:25 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-07 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-04 07:29 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 06:02 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 07:19 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 07:12 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-16 16:01 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 07:11 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-05 06:59 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-16 16:36 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 07:21 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 07:12 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:11 ET
Regeneron Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-08 09:13 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-05 07:34 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-15 16:01 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 06:03 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-05 06:03 ET
Regeneron Pharmaceuticals published news for 2020 q4
SEC form 10
2020-11-05 07:48 ET
Regeneron Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 07:32 ET
Regeneron Pharmaceuticals published news for 2020 q3